RMX Biopharma Co., Ltd (Headquartered in Hangzhou, China, CEO: RuiPing Dong, “RMX”), initiated a clinical study with EP4 antagonist AAT-007 in the People’s Republic of China (China) on September 20, 2018.  RMX licensed AskAt Inc.’s EP4 antagonist AAT-007 (generic name: grapiprant) for pain indications in China on January 1, 2016.

This is the first clinical trial in China.  AAT-007 has previously demonstrated efficacy, safety, and tolerability in Phase 2 clinical trials in the United States for osteoarthritis-associated pain.